VDA 1102

Drug Profile

VDA 1102

Alternative Names: VDA-1102

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator VidacPharma
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Hexokinase inhibitors; Keratinocyte modulators; Voltage-dependent anion channel modulators; Voltage-gated potassium channel modulators; Voltage-gated sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Actinic keratosis
  • Preclinical Cutaneous T cell lymphoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 01 Jul 2016 Phase-II clinical trials in Actinic keratosis in USA (Topical) (NCT02844777)
  • 29 Jun 2016 VidacPharma completes a phase I trial in Actinic keratosis in USA
  • 04 May 2016 Pharmacodynamics and adverse events data from preclinical studies in Actinic keratosis and Squamous cell carcinoma presented at the 74th Annual Meeting of the American Academy of Dermatology (AAD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top